This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Axonal loss from relapses and neurodegeneration is a main element of multiple sclerosis (MS) pathology, so an objective biomarker to detect and quantify it should be of great value. Neurofilaments belong to the intermediate filament family of proteins and are the major components of the cytoskeleton of neurons. They consist of 3 isotypes: a neurofilament light (NfL) chain of 68 kDa, a neurofilament intermediate (NfM) chain of 150 kDa, and a neurofilament heavy (NfH) chain of 190 to 210 kDa.1 During the process of axonal injury, intracellular components, including neurofilaments, are released into the extracellular fluid and subsequently into the CSF. Thus, analysis of neurofilament levels in the CSF may reliably capture the extent of axonal damage and neurodegeneration in the CNS, regardless of the underlying cause.1 Evidence for increased CSF neurofilament levels in MS mainly exists for NfH and NfL, whereas NfM has not been extensively studied so far.1 Several test systems exist to determine NfH and NfL, and a commercially available ELISA to detect NfL is advantageous in discriminating patients with MS from controls.2
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the editorial.
See page 1076
- © 2016 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Costs and Utilization of New-to-Market Neurologic Medications
Dr. Robert J. Fox and Dr. Mandy Leonard